**Associations of schizophrenia risk genes *ZNF804A* and *CACNA1C* with schizotypy and modulation of attention in healthy subjects**

**Authors:** Tina Mellera,b, Simon Schmitta,b, Frederike Steina, Katharina Broscha,b, Johannes Mosebacha, Dilara Yüksela,c,d, Dario Zarembae, Dominik Grotegerde, Katharina Dohme, Susanne Meinerte, Katharina Förstere, Ronny Redliche, Nils Opele, Jonathan Repplee, Tim Hahne, Andreas Jansena,b,f, Till F. M. Andlauerg,h, Andreas J. Forstneri,j,l,m, Stefanie Heilmann-Heimbachi, Fabian Streitk, Stephanie H. Wittk, Marcella Rietschelk, Bertram Müller-Myhsokg,n,o, Markus M. Nötheni, Udo Dannlowskie, Axel Kruga,b,c, Tilo Kirchera,b,c, Igor Nenadića,b,c

a Department of Psychiatry and Psychotherapy, Philipps-Universität Marburg, Rudolf-Bultmann-Str. 8, 35039 Marburg, Germany

b Center for Mind, Brain and Behavior (CMBB), Hans-Meerwein-Str. 6, 35032 Marburg, Germany

c Marburg University Hospital – UKGM, Rudolf-Bultmann-Str. 8, 35039 Marburg, Germany

d SRI International, Center for Health Sciences, Bioscience Division, 333 Ravenswood Avenue, 94025 Menlo Park, California, USA

e Department of Psychiatry and Psychotherapy, Westfälische Wilhelms-Universität Münster, Albert-Schweitzer-Campus 1, Building A9, 48149 Münster, Germany

f Core-Facility BrainImaging, Faculty of Medicine, Rudolf-Bultmann-Str. 8, 35039 Philipps-Universität Marburg

g Max-Planck-Institute of Psychiatry, Kraepelinstr. 2-10, 80804 Munich, Germany

h Department of Neurology, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Straße 22, 81675 Munich, Germany

i Institute of Human Genetics, University of Bonn School of Medicine & University Hospital Bonn, Sigmund-Freud-Straße 25, 53127 Bonn, Germany

j Institute of Human Genetics, Philipps-Universität Marburg, Baldingerstraße, 35033 Marburg, Germany

k Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, J5, 68159 Mannheim, Germany

l Department of Biomedicine, University of Basel, Hebelstrasse 20, 4031 Basel, Switzerland

m Institute of Medical Genetics and Pathology, University Hospital Basel, Schönbeinstr. 40, 4056 Basel, Switzerland

n Munich Cluster for Systems Neurology (SyNergy), Feodor-Lynen-Str. 17

81377 Munich, Germany

o Institute of Translational Medicine, University of Liverpool, Crown Street, Liverpool L69 3BX, UK

**Corresponding author:** Dipl.-Psych. Tina Meller

Department of Psychiatry and Psychotherapy, Philipps-Universität Marburg, Rudolf-Bultmann-Str. 8, 35039 Marburg, Germany

Phone: +49-6421-58 63832

Fax: +49-6421-58 68939

Email: tina.meller@staff.uni-marburg.de

**Word count:** 3.945**Abstract**

Schizotypy is a multidimensional risk phenotype distributed in the general population, constituting of subclinical, psychotic-like symptoms. It is associated with psychosis proneness, and several risk genes for psychosis are associated with schizotypy in non-clinical populations. Schizotypy might also modulate cognitive abilities as it is associated with attentional deficits in healthy subjects. In this study, we tested the hypothesis that risk variants *ZNF804A* rs1344706 and *CACNA1C* rs1006737 are associated with psychometric schizotypy and that schizotypy mediates their effect on attention as a key aspect of cognition. In 615 psychiatrically healthy subjects from the FOR2107 cohort study, we analysed the established risk variants, psychometric schizotypy (schizotypal personality questionnaire-brief SPQ-B), and a neuropsychological measure of sustained and selective attention (d2 test). *ZNF804A* rs1344706 C (non-risk) alleles were significantly associated with higher SPQ-B Cognitive-Perceptual subscores in women and with attention deficits in both sexes. This schizotypy dimension also mediated the effect of *ZNF804A* on attention in women, but not in men. *CACNA1C* rs1006737-A showed a significant sex-modulated negative association with Interpersonal schizotypy only in men, and no effect on attention. Our multivariate model demonstrates differential genetic contributions of two psychosis risk genes to dimensions of schizotypy and, partly, to attention. This supports a model of shared genetic influence between schizotypy and cognitive functions impaired in schizophrenia.

**Keywords:** schizotypy; attention;cognition; schizophrenia risk variants; psychosis

**1. Introduction**

Schizotypy is a multidimensional construct of personality traits phenomenologically resembling subclinical schizophrenia symptoms. It is considered a phenotypic marker of psychosis proneness and schizophrenia risk (Barrantes-Vidal et al., 2015) and elevated in patients with psychotic disorders (Brosey and Woodward, 2015). Schizotypy, having predictive value for conversion probability into schizophrenia-spectrum disorders (Chapman et al., 1994; Gooding et al., 2005; Kwapil et al., 2013), is also considered a high-risk marker in early intervention research.

The phenotype comprises aspects of deviations in cognition, emotion, speech, and perception (Ettinger et al., 2015), but is also associated with higher creativity (Fink et al., 2014; Mohr and Claridge, 2015), possibly even constituting an evolutionary advantage (Nettle and Clegg, 2006). Schizotypy is often delineated into the three dimensions *positive/cognitive-perceptual* (magical thinking, referential ideas, unusual perceptual experiences, and paranoid ideation), *negative/interpersonal* (difficulties in social interaction and blunted affect) and *disorganised* (“odd” speech and behaviour).

While different cognitive dimensions have been linked to schizotypy (Siddi et al., 2017), relative deficits in sustained and selective attention are robustly reported (Breeze et al., 2011; Fuggetta et al., 2015; Gooding et al., 2006; Moreno-Samaniego et al., 2017). Findings even point to a possible genetic link between attention-deficit hyperactivity disorder and schizotypy (Ettinger et al., 2006). While impaired attention has often been associated with the negative schizotypy dimension (Alvarez-Moya et al., 2007; Chen and Faraone, 2000; Smyrnis et al., 2007), recent evidence also suggests the cognitive-perceptual dimension as a risk factor for attentional difficulties (Gooding et al., 2006; Stotesbury et al., 2018). Attention deficits are also found in schizophrenia patients compared to healthy controls (Elvevåg and Goldberg, 2000; Hill et al., 2008; Lee et al., 2017; Nuechterlein et al., 2004), and in first-degree relatives of schizophrenia patients (Snitz et al., 2005), indicating genetic effects. Attention therefore represents a putative cognitive link between these risk genotypes and phenotypes.

Growing evidence also suggests a partially shared genetic basis between schizotypy and psychotic disorders. Genome-wide association studies (GWAS) have currently identified more than 120 common genetic variations contributing to the risk for schizophrenia (Pardiñas et al., 2018), and while at least some risk genes are shared among clinical psychosis phenotypes (Craddock et al., 2009; Sheldrick et al., 2008), there is growing evidence that polygenic risk scores for psychosis are only marginally associated with schizotypy (Hatzimanolis et al., 2018; Jones et al., 2016). However, recent studies reporting significant associations of schizophrenia risk variants with schizotypy measures support a partially mutual genetic background (Barrantes-Vidal et al., 2015).

Among the most prominent susceptibility genes for schizophrenia is *ZNF804A*,involved in neurodevelopmental processes (Lencz et al., 2010) andcoding for the zinc-finger binding protein 804A (Voineskos et al., 2011). The major A allele of the single-nucleotide polymorphism (SNP) rs1344706 was initially reported to be associated with schizophrenia in a GWAS by O’Donovan et al., with an even stronger association to a broader psychosis phenotype that includes bipolar disorder (O’Donovan et al., 2008). This association has since been replicated and shown to be one of the strongest susceptibility variants for schizophrenia (Pardiñas et al., 2018; Riley et al., 2010; Williams et al., 2011). Rs1344706-A has been associated with decreased expression of *ZNF804A* in fetal brain tissue (Hill and Bray, 2012) and with neurocognitive and brain structural variations in schizophrenia patients and in healthy controls (Chang et al., 2017; Donohoe et al., 2011; Nenadic et al., 2015). Two recent studies linked *ZNF804A* rs1344706 with schizotypy (Stefanis et al., 2013; Yasuda et al., 2011), but with heterogeneous dimensional associations: While Yasuda and colleagues found carriers of the rs1344706 major A-allele to have higher disorganised schizotypal levels, Stefanis et al. reported the opposite effect, i.e., a positive association of the minor C-allele with positive schizotypy, calling for further research.

A second gene strongly associated with the psychosis spectrum is *CACNA1C*, encoding a subunit of the calcium channel Cav1.2, which is involved in the modulation of gene transcription, synaptic plasticity and cell survival in the brain (Bhat et al., 2012). *CACNA1C*’s intronic SNP rs1006737 with risk allele A has been established as a susceptibility variant for schizophrenia (Jiang et al., 2015; Ripke et al., 2013; Ruderfer et al., 2014) and bipolar disorder (Ferreira et al., 2008; Moon et al., 2018; Ruderfer et al., 2014). It has been associated with cognitive variation like decreased attentional performance (Thimm et al., 2011), impaired working memory (Zhang et al., 2012), but also impaired facial emotion recognition (Soeiro-de-Souza et al., 2012) and increased interpersonal distress (Erk et al., 2010). In two previous studies, rs1006737-A has also been linked to elevated positive schizotypy and schizotypal personality disorder (Roussos et al., 2013, 2011). While the influence of *CACNA1C* variants on cognition and its neural correlates has been shown repeatedly (Dietsche et al., 2014; Krug et al., 2014), it is unclear whether the gene is also linked to variation in cognitive function in schizotypy.

Taken together, current research suggests an association of psychosis risk genes *ZNF804A* and *CACNA1C* with impaired cognition and schizotypy in the general population, and an association of both schizophrenia and schizotypy with cognitive deficits. It is, however, lacking models integrating those univariate associations into a joint framework. As there are known sex differences in schizophrenia prevalence and symptom profiles (Abel et al., 2010) as well as schizotypy (Kremen et al., 1998; Raine, 1992); and sex-specific effects have recently been reported for both genes (de Castro-Catala et al., 2017; Strohmaier et al., 2013), a differential impact for males and females should be considered.

Therefore, the first aim of the present study was to analyse the differential effects of *ZNF804A* rs1344706 and *CACNA1C* rs1006737 on dimensional schizotypy as a phenotypic psychosis proneness marker, considering sex-dependent modulations. Secondly, we tested the opposing models of (a) the relatively stable personality trait schizotypy mediating genetic influence on attention, expecting the *Cognitive-Perceptual* dimension to particularly affect cognition as recently suggested (Stotesbury et al., 2018) and (b) attentional variation explaining mediating genetic influence on schizotypal traits, as derived from recent studies of cognition in schizophrenia (Toulopoulou et al., 2018, 2015).

**2. Material and methods**

*2.1 Sample*

We analysed data of 615 healthy Central European subjects (age 18-65 years, mean=32.77, standard deviation (SD)=12.50) drawn from the FOR2107 cohort, a multi-centre study through newspaper advertisements and mailing lists from the areas of Marburg and Muenster in Germany (Kircher et al., 2018). Ethics approval was obtained from the ethics committees of the Medical Schools of the Universities of Marburg and Muenster, respectively, in accordance with the Declaration of Helsinki. All subjects volunteered to participate in the study and provided written informed consent. Subjects of non-European origin were excluded from the analyses because of known population differences in the studied genetic polymorphisms. Exclusion criteria were current or former psychiatric disorders (assessed with SCID-I interviews (Wittchen et al., 1997) by trained raters), history of neurological or other severe medical disorders, verbal IQ <80 (Multiple Choice Word Test-B (Lehrl, 1995)), or current psychotropic medication. The resulting sample comprised 232 (37.7%) male and 383 (62.3%) female participants.

*2.2 Assessment of psychometric schizotypy*

Self-reported schizotypy was assessed with the German version (Klein et al., 1997) of the Schizotypal Personality Questionnaire-Brief (SPQ-B (Raine and Benishay, 1995)). Based on Raine’s original SPQ (Raine, 1991), it has recently been validated across multi-national studies, including the German version (Fonseca-Pedrero et al., 2018). Beside a total schizotypy score, the SPQ-B provides measures on the *Cognitive-Perceptual*, *Interpersonal*, and *Disorganised* dimensions delineated by previous factor analyses (Axelrod et al., 2001; Compton et al., 2009). For the questionnaire as a whole and its subscores, adequate internal consistency and criterion validity have been demonstrated (Fonseca-Pedrero et al., 2018; Klein et al., 2001). In our sample, the SPQ-B showed acceptable reliability (Cronbach’s α=0.737).

*2.3 Neurocognitive testing*

Participants underwent standardised neurocognitive testing for sustained and selective attention with the d2 test of attention (Brickenkamp, 2002). It is a cancellation test assessing the continuous ability to focus on task-relevant characteristics while ignoring similar characters, requiring visual perceptual speed and accuracy. Despite its simple structure and implementation, the d2 test has been shown to be a reliable and valid measure of attention capacity, both in healthy subjects and in schizophrenia patients (Brickenkamp, 2002; Lee et al., 2017). The *concentration performance* parameter (the error-adjusted number of hits) was used in this analyses as it is resistant to deception attempts and highly reliable in the reference sample (Brickenkamp, 2002) and a randomly drawn subset of our own sample (Cronbach’s alpha α=0.981).

*2.4 Genotyping and quality control*

Genomic DNA was extracted from blood samples acquired onsite. Genotyping and further preparation of genomic data was performed blinded to phenotype data at the Institute of Human Genetics of the University Hospital Bonn, Germany and at the Max Planck Institute of Psychiatry, Munich, Germany. Genotyping was conducted using the Infinium PsychArray BeadChip (Illumina, San Diego, CA, USA), according to standard protocols. Clustering and initial QC was conducted in GenomeStudio v.2011.1 (Illumina, San Diego, USA) with the Genotyping Module v.1.9.4. Full QC was performed in PLINK v1.90b5 (Chang et al., 2015) and *R* v3.3.3, based on a larger dataset of which the present subjects constituted a subset. Individuals were removed if they met any of the following criteria: genotyping call rate <98%, gender mismatches or other X-chromosome-related issues, genetic duplicates, cryptic relatives with pi-hat ≥12.5%, genetic outlier with a distance from the mean of >4 SD in the first eight ancestry components, or a deviation of the autosomal or X-chromosomal heterozygosity from the mean >4 SD.

*2.5 Statistical analyses*

Sex differences in schizotypy, age, and neurocognitive performance were analysed using Student’s *t*-tests for independent samples or Mann-Whitney *U* tests where the assumption of normal distribution was violated. Distributions of allelic frequencies between sexes were compared with chi-squared (*χ2*) tests. Associations of genotypes and schizotypy were analysed via linear regression models, using the IBM Statistical Package for Social Sciences (SPSS, version 22, IBM, Armonk, NY) and the PROCESS macro v3.1 for SPSS (Hayes, 2013). Multidimensional scaling (MDS) analyses to estimate population stratification in the sample were conducted in PLINK (Purcell & Chang; Chang et al. 2015), the first three MDS components were included as covariates in SNP association analyses. Leave-one-out cross-validation was used to calculate the root mean PRESS (predicted residual error sum of squares) as a model fit parameter in stepwise regressions (√mPRESS). As SPQ-B scales are correlated, *p*-values were adjusted (*padj*) to correct for multiple comparison according to Bonferroni-Holm (Holm, 1979), using *R* (R Core Team, 2018).

**3. Results**

*3.1 Distribution of schizotypy, attention, and allele frequencies*

Descriptive statistics for SPQ-B subscores as well as genotype frequencies for *ZNF804A* rs1344706 and *CACNA1C* rs1006737 are shown in Table 1. Neither rs1344706 (*χ2*(degrees of freedom (*df)*=2)=0.79, *p*=0.675) nor rs1006737 (*χ2*(2)=3.80, *p*=0.150) showed significant differences in minor allele counts between sexes. We also found no significant sex differences for age (*t*(613)=-0.379, *p=*0.704; male mean=32.52, SD=11.49, female mean=32.92, SD=13.09) or d2 performance (*t*(613)=-1.45, *p*=0.148). Mean d2 scores for the whole sample (mean=191.40, SD=42.25), as well as for males (mean=188.24, SD=41.75) and females (mean=193.32, SD=42.49), were within the average range for healthy subjects, according to standard tables (Brickenkamp, 2002). As observed in previous studies (Kremen et al., 1998; Raine, 1992), we found significant sex differences for the SPQ-B *Sum* score (*U*=-2.45, *p*=0.014, *p*adj=0.028), the *Interpersonal* (*U*=-2.43, *p*=0.015, *p*adj=0.028) and *Disorganised* (*U*=-3.84, *p*=1.3×10-4, *p*adj=3.9×10-4) subscores, with higher scores in males than in females; but not for the *Cognitive-Perceptual* (*U*=-0.96, *p*=0.336) subscore.

*3.2 Associations of ZNF804A, CACNA1C and schizotypy dimensions*

To explore the prediction of the three schizotypy dimensions, we performed separate stepwise multiple regression analyses, entering thetwo SNPs, SNP×sex interaction terms, sex, age, and MDS components as possible regressors (Table 2, Suppl. Table S1a-1c).

For the *Cognitive-Perceptual* dimension (*model 1a,* √mPRESS=1.12, Figure 1), we found a significant effect of age (β=0.018, *p*=5.05×10-7, *p*adj=2.53×10-6) and rs1344706×sex (β=0.089, *p*=0.015, *p*adj=0.033), with a higher number of C alleles associated with higher *Cognitive-Perceptual* schizotypy in females (β=0.212, *p*=0.007), but not in males (β=-0.071, *p*=0.458).

For the *Interpersonal* dimension (*model 1b,* √mPRESS=1.71, Figure 1), we also found a significant effect of age (β=0.011, *p*=0.044, *p*adj=0.044) and rs1006737×sex (β=-0.150, *p*=0.011, *p*adj=0.033), with a higher number of A alleles associated with lower *Interpersonal* schizotypy in males (β=-0.399, *p*=0.035), but not in females (β=-0.162, *p*=0.209).

For the *Disorganised* dimension (*model 1c*), only sex was identified as a significant regressor (β=-0.390, *p*=2.16×10-4, *p*adj=8.64×10-4).

Total schizotypy was neither associated with *ZNF804A* rs1344706 (β=-0.317, *p*=0.591) nor *CACNA1C* rs1006737 (β=-0.227, *p*=0.120).

*3.3 Associations of ZNF804A, CACNA1C, schizotypy dimensions and attention*

To explore significant predictors of d2 performance, we calculated a separate stepwise multiple regression *model 2* with the two SNPs, SNP×sex interaction terms, sex, age, the three schizotypy subscores, and MDS components as possible regressors (√mPRESS=37.99, Table 2, Suppl. Table S2). Here, age (β=-1.342, *p*=7.82×10-25, *p*adj=3.14×10-24), *Cognitive-Perceptual* schizotypy (β=-4.509, *p*=0.001, *p*adj=0.003), *ZNF804A* rs1344706 (β=-15.551, *p*=0.003, *p*adj=0.006) and rs1344706×sex (β=6.553, *p*=0.026, *p*adj=0.026), with a higher number of rs1344706-C associated with lower d2 performance in males (β=-8.145, *p*=0.017) but not in females (β=-3.041, *p*=0.292), were detected as significant regressors.

*3.4 Mediation models of ZNF804A, schizotypy and attention*

To analyse the proposed mediating relationship of schizotypy and attention, we hypothesised two models, derived from the associations detected in the regression models *1a-c* and *2*. *Model 3a* (Figure 2, Suppl. Table S3) proposes *Cognitive-Perceptual* schizotypy as a risk factor for impaired cognition, thus mediating the effect of rs1344706 on d2 performance (*F*(3,611)=48.78, *p* <1×10-100, *R²*=0.197). We found a significant direct effect of the dosage of *ZNF804A* rs1344706-C (c’=-5.038, *t*(611)=-2.31, *p*=0.021, *padj*=0.032) as well as a significant indirect effect of the SNP via *Cognitive-Perceptual* schizotypy (β=-4.210, *t*(611)=-2.94, *p*=0.003, *padj*=0.013) on d2 performance. However, the latter was again moderated by sex: Only for females (β=-0.890) but not for males (β=0.300), a bootstrap-based confidence interval calculated using 10 000 bootstrap samples was consistently below zero, confirming a conditional indirect effect.

We additionally considered the opposing model, assuming cognition at an intermediate position between genes and phenotype. We tested this assumption in our data, with d2 performance mediating the sex-moderated effect of rs1344706-C on *Cognitive-Perceptual* schizotypy. This *model 3b* (Figure 3, suppl. Table S3), although significant, explained a smaller proportion of the variance (*F*(5,609)=6.90, *p*=2.4×10-6, *R²*=0.071) than *model 3a*. Post hoc *t*-tests comparing absolute z-transformed bootstrapped coefficient estimates from *models 3a* and *3b* revealed a stronger effect of rs1344706 on *Cognitive-Perceptual* schizotypy than on d2 performance (mean absolute difference (mad, *3a*)=0.130, SD=0.117; mad(*3b*)=0.134, SD=0.117) in both models (*t*(9999)=-111.49, *p* <1×10-100; *t*(9999)=-114.47, *p* <1×10-100, respectively).

There was no indication of a mediating effect of *Interpersonal* schizotypy on the association of CACNA1C rs1006737-A on attention or vice versa (suppl. Table S4a-b).

**4. Discussion**

This is the first large-scale study addressing the interplay between candidate susceptibility genes for psychotic disorders with different dimensions of schizotypy and neurocognitive performance as a putative endophenotype for psychosis in healthy subjects. Our analysis provides first support for a multivariate model of the interaction of genotype, phenotype, and cognition, linking schizotypy in the general population to a dimensional schizophrenia model. This includes two major findings: We observe, for the first time, a sex-moderated association of *ZNF804A* rs1344706 with the SPQ-B *Cognitive-Perceptual* dimension and of *CACNA1C* rs1006737 with the SPQ-B *Interpersonal* dimension. We suggest a moderated mediation model showing that in women, the effect of rs1344706 on attention is mediated by *Cognitive-Perceptual* schizotypy*.* Our results have implications for the role of *ZNF804A* rs1344706 and CACNA1c rs1006737 in schizotypy and cognitive function, and suggest a sex-modulated interaction between them.

Concurrent with previous findings (Stefanis et al., 2013; Yasuda et al., 2011), we further confirmed *ZNF804A* rs1344706 as susceptibility SNP for schizotypy. While this association has previously been reported, we provide a more detailed link to particular schizotypy dimensions, modulated by sex. Initially, Yasuda *et al.,* reported a positive relationship between *ZNF804A* rs1344706-A and *Disorganised* schizotypal traits in healthy subjects (Yasuda et al., 2011). Concurrent with our own findings, however, Stefanis *et al.* reported an inverse relationship, with a higher number of rs1344706-A associated with decreased schizotypy. This effect was found for a primarily “positive” schizotypy endophenotype, including referential ideas and perceptual aberrations (Stefanis et al., 2013), in line with our results linking rs1344706 to the *Cognitive-Perceptual* dimension. Differences to Yasuda’s findings might be attributed to divergent study populations and genetic backgrounds (Japanese vs. Central-European) and different A allele frequencies in those populations (38% and 61%, respectively (Clarke and Cardon, 2010; Yasuda et al., 2011)).

We now extend the simple model of a direct dependence of schizotypal features on rs1344706 allelic load by introducing sex as moderator. While previous studies on rs1344706 were either confined to all male samples (Stefanis et al., 2013) or did not test for such an interaction (Yasuda et al., 2011), a similar finding for another schizophrenia susceptibility SNP of *ZNF804A* (rs7597593, in medium linkage disequilibrium with rs1344706; *r²*=0.395 calculated with LDlink for the CEU population (Machiela and Chanock, 2015)) has recently been reported, as only female C allele carriers showed elevated schizotypy levels compared to A-homozygotes (de Castro-Catala et al., 2017). Sex-dependent effects of rs7597593 are also evident in clinical measures and post-mortem brain mRNA expression levels in schizophrenia (Zhang et al., 2011). Thus, our findings can be explained with clinical and molecular mechanisms causing sex×SNP interactions for *ZNF804A* in the development of schizotypal traits.

In addition, we confirmed recent findings relating *ZNF804A* rs1344706 to neurocognitive function in general, and attention in particular (Chang et al., 2017). In healthy participants, the A allele and A/A genotype was associated with deficits in the executive control dimension of attention (Balog et al., 2011). Proposing a neural correlate of functional alterations, rs1344706-A homozygotes showed reduced thickness within the anterior cingulate cortex (Voineskos et al., 2011) and changes in functional coupling of the dorsolateral prefrontal cortex with the hippocampus (Esslinger et al., 2009; Paulus et al., 2013). Interestingly, in patients with schizophrenia, A allele load has been associated with fewer cognitive deficits (Van Den Bossche et al., 2012; Walters et al., 2010) and decreased cortical alteration (Schultz et al., 2014). It has been suggested that *ZNF804A* rs1344706 may enhance susceptibility to a certain schizophrenia subtype with less cognitive impairment (Walters et al., 2010), but also that the effects of rs1344706 might differ between healthy participants and patients (Hargreaves et al., 2012).

While Stefanis *et al.* linked *ZNF804A* SNPs to schizotypy, they did not detect an effect of rs1344706 on neuropsychological measures (Stefanis et al., 2013). Differences in test batteries aside, the discrepancy between their findings and our own may be caused by marked differences in sample characteristics. Their sample comprised of young male army recruits while ours combined female and male participants within a wide range of age. Given the well-known age effects on neurocognitive measures (Lufi et al., 2015), a very selective sample with reduced variance might thus underestimate correlation or regression measures.

Despite evidence linking *ZNF804A* rs1344706 to illness susceptibility and psychosis proneness, neurocognitive functions, and variations in brain structure and function, its exact biological pathway is still unclear. *ZNF804A* is expressed widely in the human brain (Sun et al., 2015), especially within the dorsolateral prefrontal cortex and the hippocampus (Hill and Bray, 2012). Rs1344706 is non-coding but thought to have effects on *ZNF804A* expression (Hill and Bray, 2011), particularly during early prenatal brain development (Hill and Bray, 2012). *ZNF804A* has also been associated with regulation of dopamine receptors (Girgenti et al., 2012), and alterations of dopamine concentration, and expression of dopaminergic genes have been linked to psychosis etiology (Howes and Kapur, 2009) and schizotypy (Grant et al., 2014; Mohr and Ettinger, 2014). In addition, sex-specific effects of genes involved in dopamine transmission have been discussed in schizophrenia, with oestrogens and androgens differentially modifying the development of schizophrenia symptoms through dopaminergic pathways (Godar and Bortolato, 2014). Similar mechanisms might influence the development of subclinical symptoms in schizotypy and thus explain sex-dependent effects of *ZNF804A* on schizotypal traits.

Taken together, compelling evidence suggests that effects of *ZNF804A* rs1344706 polymorphisms have a relevant impact long before potential illness manifestation. Affected brain areas and neurocognitive functions have shown to be relevant for schizophrenia as well as schizotypy. Using genetic modelling in twin samples, Toulopoulou *et al*. showed that a substantial part of the phenotypic overlap between schizophrenia and cognition is explained by shared genetic variability (Toulopoulou et al., 2007). The authors concluded that the next step would be to identify specific genes that influence schizophrenia together with cognitive quantities. Our results support *ZNF804A* rs1344706 as such a genetic variant relevant for schizotypy, an intermediate schizophrenia phenotype. As has been reported recently (Stotesbury et al., 2018), we particularly regard the *Cognitive-Perceptual* dimension as a risk factor for attentional difficulties.

However, Toulopoulou *et al*. subsequently argued that schizophrenia liability is partially expressed through cognitive deficits (Toulopoulou et al., 2015) and that cognitive functions lie upstream of schizophrenia (Toulopoulou et al., 2018). Relevant loci should then have a bigger effect on cognitive function than on schizophrenia (Toulopoulou et al., 2015). Our results, however, fail to confirm this prediction for the schizotypy phenotype. In both models tested, *ZNF804A* rs1344706 showed a larger effect on schizotypy than on cognitive function. While aware that this cannot definitively be resolved in our cross-sectional study, we believe that our results should inspire further dissection of the proposed models. Considerably, Toulopoulou’s model is based on net genetic influences rather than single risk variants. It also relies on patient data and thus on the schizophrenia phenotype rather than schizotypy (Hargreaves et al., 2012) and *ZNF804A* expression seems to differ between schizophrenia patients and healthy controls (Guella and Vawter, 2014). The underlying mechanisms of schizophrenia and schizotypy are overlapping, but most likely not identical. Besides a balanced proportion of male and female participants, the application of multiple measures of both schizotypy and cognitive performance should be considered to overcome limitations of our own study.

We further showed a sex-modulated association of the psychosis susceptibility variant rs1006737 in *CACNA1C* with the *Interpersonal* schizotypy dimension. While sex-dependent effects of rs1006737 or its proxy rs10774035 have been reported for schizophrenia-spectrum disorders (Heilbronner et al., 2015) and emotional lability and resilience (Strohmaier et al., 2013), this is, to our knowledge, the first study detecting a sex-dependent effect of rs1006737 on schizotypy. In contrast to previous studies (Roussos et al., 2013, 2011), associating rs1006737-A with higher *Paranoid Ideation,* we find an inverse relationship, *i.e.* with lower *Interpersonal* schizotypy scores in men only. Beside the possibility of chance findings, this might be due to differences in sample characteristics, as both studies by Roussos *et al.* analysed young male army recruits, while our sample comprised males and females of a wide age range. Other discrepancies include the schizotypy measures and possible population differences (Greek vs. Central European) across studies (Clarke and Cardon, 2010).

As *CACNA1C* is suggested to be a susceptibility gene for a more general risk for mental illness (Cross-Disorder Group of the Psychiatric Genomics Consortium, 2013), divergent effects in different studies might represent a less specific impact of the SNP. This would implicate the need for more studies with diverse samples. However, *CACNA1C* rs1006737 has repeatedly been associated with socially relevant tasks like emotion recognition and processing (Nieratschker et al., 2015; Soeiro-de-Souza et al., 2012; Tesli et al., 2013), as well as alterations in social interaction in animal models (Dedic et al., 2018; Moon et al., 2018). Thus, variations in rs1006737 seem to affect social functioning on a behavioural level, as well as brain structural and functional correlates. It might be concluded that rs1006737 primarily affects the *Interpersonal* and, as such, social dimension of schizotypy.

The results from our study provide evidence for the involvement of schizophrenia genetic susceptibility variants in psychometric schizotypy, a risk phenotype for psychosis. Our findings further provide an account of how those risk variants might modulate different dimensions of individual schizotypal traits even in healthy subjects, affecting neurocognitive performance in domains frequently impaired in schizophrenia.

**References**

Abel, K.M., Drake, R., Goldstein, J.M., 2010. Sex differences in schizophrenia. Int. Rev. Psychiatry 22, 417–428. https://doi.org/10.3109/09540261.2010.515205

Alvarez-Moya, E.M., Barrantes-Vidal, N., Navarro, J.B., Subira, S., Obiols, J.E., 2007. Exophenotypical profile of adolescents with sustained attention deficit: A 10-year follow-up study. Psychiatry Res. 153, 119–130. https://doi.org/10.1016/j.psychres.2006.12.021

Axelrod, S.R., Grilo, C.M., Sanislow, C., McGlashan, T.H., 2001. Schizotypal Personality Questionnaire-Brief: factor structure and convergent validity in inpatient adolescents. J. Pers. Disord. 15, 168–79.

Balog, Z., Kiss, I., Kéri, S., 2011. ZNF804A may be associated with executive control of attention. Genes, Brain Behav. 10, 223–227. https://doi.org/10.1111/j.1601-183X.2010.00657.x

Barrantes-Vidal, N., Grant, P., Kwapil, T.R., 2015. The role of schizotypy in the study of the etiology of schizophrenia spectrum disorders. Schizophr. Bull. 41 Suppl 2, S408-16. https://doi.org/10.1093/schbul/sbu191

Bhat, S., Dao, D.T., Terrillion, C.E., Arad, M., Smith, R.J., Soldatov, N.M., Gould, T.D., 2012. CACNA1C (Cav1.2) in the pathophysiology of psychiatric disease. Prog. Neurobiol. 99, 1–14. https://doi.org/10.1016/j.pneurobio.2012.06.001

Breeze, J.M.B., Kirkham, A.J., Marí-Beffa, P., 2011. Evidence of reduced selective attention in schizotypal personality disorder. J. Clin. Exp. Neuropsychol. 33, 776–784. https://doi.org/10.1080/13803395.2011.558495

Brickenkamp, R., 2002. Der Aufmerksamkeits-Belastungstest d2, 9th ed. Hogrefe, Goettingen.

Brosey, E., Woodward, N.D., 2015. Schizotypy and clinical symptoms, cognitive function, and quality of life in individuals with a psychotic disorder. Schizophr. Res. 166, 92–97. https://doi.org/10.1016/j.schres.2015.04.038

Chang, C.C., Chow, C.C., Tellier, L.C., Vattikuti, S., Purcell, S.M., Lee, J.J., 2015. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience 4, 7. https://doi.org/10.1186/s13742-015-0047-8

Chang, H., Xiao, X., Li, M., 2017. The schizophrenia risk gene ZNF804A: Clinical associations, biological mechanisms and neuronal functions. Mol. Psychiatry 22, 944–953. https://doi.org/10.1038/mp.2017.19

Chapman, L.J., Chapman, J.P., Kwapil, T.R., Eckblad, M., Zinser, M.C., 1994. Putatively psychosis-prone subjects 10 years later. J. Abnorm. Psychol. 103, 171–83.

Chen, W.J., Faraone, S. V, 2000. Sustained attention deficits as markers of genetic susceptibility to schizophrenia. Am. J. Med. Genet. 97, 52–7.

Clarke, G.M., Cardon, L.R., 2010. Aspects of observing and claiming allele flips in association studies. Genet. Epidemiol. 34, 266–74. https://doi.org/10.1002/gepi.20458

Compton, M.T., Goulding, S.M., Bakeman, R., McClure-Tone, E.B., 2009. An examination of the factorial structure of the Schizotypal Personality Questionnaire-Brief (SPQ-B) among undergraduate students. Schizophr. Res. 115, 286–289. https://doi.org/10.1016/J.SCHRES.2009.04.012

Craddock, N., O’Donovan, M.C., Owen, M.J., 2009. Psychosis genetics: modeling the relationship between schizophrenia, bipolar disorder, and mixed (or &quot;schizoaffective&quot;) psychoses. Schizophr. Bull. 35, 482–90. https://doi.org/10.1093/schbul/sbp020

Cross-Disorder Group of the Psychiatric Genomics Consortium, 2013. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 381, 1371–1379. https://doi.org/10.1016/S0140-6736(12)62129-1

de Castro-Catala, M., Mora-Solano, A., Kwapil, T.R., Cristóbal-Narváez, P., Sheinbaum, T., Racioppi, A., Barrantes-Vidal, N., Rosa, A., 2017. The genome-wide associated candidate gene ZNF804A and psychosis-proneness: Evidence of sex-modulated association. PLoS One 12, e0185072. https://doi.org/10.1371/journal.pone.0185072

Dedic, N., Pöhlmann, M.L., Richter, J.S., Mehta, D., Czamara, D., Metzger, M.W., Dine, J., Bedenk, B.T., Hartmann, J., Wagner, K. V, Jurik, A., Almli, L.M., Lori, A., Moosmang, S., Hofmann, F., Wotjak, C.T., Rammes, G., Eder, M., Chen, A., Ressler, K.J., Wurst, W., Schmidt, M. V, Binder, E.B., Deussing, J.M., 2018. Cross-disorder risk gene CACNA1C differentially modulates susceptibility to psychiatric disorders during development and adulthood. Mol. Psychiatry 23, 533–543. https://doi.org/10.1038/mp.2017.133

Dietsche, B., Backes, H., Laneri, D., Weikert, T., Witt, S.H., Rietschel, M., Sommer, J., Kircher, T., Krug, A., 2014. The impact of a CACNA1C gene polymorphism on learning and hippocampal formation in healthy individuals: a diffusion tensor imaging study. Neuroimage 89, 256–61. https://doi.org/10.1016/j.neuroimage.2013.11.030

Donohoe, G., Rose, E., Frodl, T., Morris, D., Spoletini, I., Adriano, F., Bernardini, S., Caltagirone, C., Bossù, P., Gill, M., Corvin, A.P., Spalletta, G., 2011. ZNF804A risk allele is associated with relatively intact gray matter volume in patients with schizophrenia. Neuroimage 54, 2132–2137. https://doi.org/10.1016/j.neuroimage.2010.09.089

Elvevåg, B., Goldberg, T.E., 2000. Cognitive impairment in schizophrenia is the core of the disorder. Crit. Rev. Neurobiol. 14, 1–21.

Erk, S., Meyer-Lindenberg, A., Schnell, K., Opitz von Boberfeld, C., Esslinger, C., Kirsch, P., Grimm, O., Arnold, C., Haddad, L., Witt, S.H., Cichon, S., Nöthen, M.M., Rietschel, M., Walter, H., 2010. Brain Function in Carriers of a Genome-wide Supported Bipolar Disorder Variant. Arch. Gen. Psychiatry 67, 803. https://doi.org/10.1001/archgenpsychiatry.2010.94

Esslinger, C., Walter, H., Kirsch, P., Erk, S., Schnell, K., Arnold, C., Haddad, L., Mier, D., Opitz von Boberfeld, C., Raab, K., Witt, S.H., Rietschel, M., Cichon, S., Meyer-Lindenberg, A., 2009. Neural mechanisms of a genome-wide supported psychosis variant. Science 324, 605. https://doi.org/10.1126/science.1167768

Ettinger, U., Joober, R., DE Guzman, R., O’Driscoll, G.A., 2006. Schizotypy, attention deficit hyperactivity disorder, and dopamine genes. Psychiatry Clin. Neurosci. 60, 764–767. https://doi.org/10.1111/j.1440-1819.2006.01594.x

Ettinger, U., Mohr, C., Gooding, D.C., Cohen, A.S., Rapp, A., Haenschel, C., Park, S., 2015. Cognition and Brain Function in Schizotypy: A Selective Review. Schizophr. Bull. 41, S417–S426. https://doi.org/10.1093/schbul/sbu190

Ferreira, M.A.R., O’Donovan, M.C., Meng, Y.A., Jones, I.R., Ruderfer, D.M., Jones, L., Fan, J., Kirov, G., Perlis, R.H., Green, E.K., Smoller, J.W., Grozeva, D., Stone, J., Nikolov, I., Chambert, K., Hamshere, M.L., Nimgaonkar, V.L., Moskvina, V., Thase, M.E., Caesar, S., Sachs, G.S., Franklin, J., Gordon-Smith, K., Ardlie, K.G., Gabriel, S.B., Fraser, C., Blumenstiel, B., Defelice, M., Breen, G., Gill, M., Morris, D.W., Elkin, A., Muir, W.J., McGhee, K.A., Williamson, R., MacIntyre, D.J., MacLean, A.W., St, C.D., Robinson, M., Van Beck, M., Pereira, A.C.P., Kandaswamy, R., McQuillin, A., Collier, D.A., Bass, N.J., Young, A.H., Lawrence, J., Ferrier, I.N., Anjorin, A., Farmer, A., Curtis, D., Scolnick, E.M., McGuffin, P., Daly, M.J., Corvin, A.P., Holmans, P.A., Blackwood, D.H., Gurling, H.M., Owen, M.J., Purcell, S.M., Sklar, P., Craddock, N., Wellcome Trust Case Control Consortium, N., 2008. Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat. Genet. 40, 1056–8. https://doi.org/10.1038/ng.209

Fink, A., Weber, B., Koschutnig, K., Benedek, M., Reishofer, G., Ebner, F., Papousek, I., Weiss, E.M., 2014. Creativity and schizotypy from the neuroscience perspective. Cogn. Affect. Behav. Neurosci. 14, 378–387. https://doi.org/10.3758/s13415-013-0210-6

Fonseca-Pedrero, E., Ortuño-Sierra, J., Lucas-Molina, B., Debbané, M., Chan, R.C.K., Cicero, D.C., Zhang, L.C., Brenner, C., Barkus, E., Linscott, R.J., Kwapil, T., Barrantes-Vidal, N., Cohen, A., Raine, A., Compton, M.T., Tone, E.B., Suhr, J., Bobes, J., Fumero, A., Giakoumaki, S., Tsaousis, I., Preti, A., Chmielewski, M., Laloyaux, J., Mechri, A., Lahmar, M.A., Wuthrich, V., Larøi, F., Badcock, J.C., Jablensky, A., Barron, D., Swami, V., Tran, U.S., Voracek, M., 2018. Brief assessment of schizotypal traits: A multinational study. Schizophr. Res. 197, 182–191. https://doi.org/10.1016/J.SCHRES.2017.10.043

Fuggetta, G., Bennett, M.A., Duke, P.A., 2015. An electrophysiological insight into visual attention mechanisms underlying schizotypy. Biol. Psychol. 109, 206–221. https://doi.org/10.1016/j.biopsycho.2015.06.007

Girgenti, M.J., LoTurco, J.J., Maher, B.J., 2012. ZNF804a Regulates Expression of the Schizophrenia-Associated Genes PRSS16, COMT, PDE4B, and DRD2. PLoS One 7, e32404. https://doi.org/10.1371/journal.pone.0032404

Godar, S.C., Bortolato, M., 2014. Gene-sex interactions in schizophrenia: focus on dopamine neurotransmission. Front. Behav. Neurosci. 8, 71. https://doi.org/10.3389/fnbeh.2014.00071

Gooding, D.C., Matts, C.W., Rollmann, E.A., 2006. Sustained attention deficits in relation to psychometrically identified schizotypy: Evaluating a potential endophenotypic marker. Schizophr. Res. 82, 27–37. https://doi.org/10.1016/J.SCHRES.2005.11.015

Gooding, D.C., Tallent, K.A., Matts, C.W., 2005. Clinical Status of At-Risk Individuals 5 Years Later: Further Validation of the Psychometric High-Risk Strategy. J. Abnorm. Psychol. 114, 170–175. https://doi.org/10.1037/0021-843X.114.1.170

Grant, P., Gabriel, F., Kuepper, Y., Wielpuetz, C., Hennig, J., 2014. Psychosis-proneness correlates with expression levels of dopaminergic genes. Eur. Psychiatry 29, 304–306. https://doi.org/10.1016/j.eurpsy.2013.12.002

Guella, I., Vawter, M.P., 2014. Allelic imbalance associated with the schizophrenia risk SNP rs1344706 indicates a cis-acting variant in ZNF804A. Schizophr. Res. 153, 243–245. https://doi.org/10.1016/J.SCHRES.2014.01.005

Hargreaves, A., Morris, D.W., Rose, E., Fahey, C., Moore, S., Cummings, E., Tropea, D., Gill, M., Corvin, A., Donohoe, G., 2012. ZNF804A and social cognition in patients with schizophrenia and healthy controls. Mol. Psychiatry 17, 118–9. https://doi.org/10.1038/mp.2011.102

Hatzimanolis, A., Avramopoulos, D., Arking, D.E., Moes, A., Bhatnagar, P., Lencz, T., Malhotra, A.K., Giakoumaki, S.G., Roussos, P., Smyrnis, N., Bitsios, P., Stefanis, N.C., 2018. Stress-dependent association between polygenic risk for schizophrenia and schizotypal traits in young army recruits. Schizophr. Bull. 44, 338–347. https://doi.org/10.1093/schbul/sbx074

Hayes, A., 2013. Introduction to mediation, moderation, and conditional process analysis: A regression‐based approach., 2nd ed. The Guilford Press.

Heilbronner, U., Malzahn, D., Strohmaier, J., Maier, S., Frank, J., Treutlein, J., Mühleisen, T.W., Forstner, A.J., Witt, S.H., Cichon, S., Falkai, P., Nöthen, M.M., Rietschel, M., Schulze, T.G., 2015. A common risk variant in CACNA1C supports a sex-dependent effect on longitudinal functioning and functional recovery from episodes of schizophrenia-spectrum but not bipolar disorder. Eur. Neuropsychopharmacol. 25, 2262–2270. https://doi.org/10.1016/j.euroneuro.2015.09.012

Hill, M.J., Bray, N.J., 2012. Evidence that schizophrenia risk variation in the ZNF804A gene exerts its effects during fetal brain development. Am. J. Psychiatry 169, 1301–8. https://doi.org/10.1176/appi.ajp.2012.11121845

Hill, M.J., Bray, N.J., 2011. Allelic differences in nuclear protein binding at a genome-wide significant risk variant for schizophrenia in ZNF804A. Mol. Psychiatry 16, 787–789. https://doi.org/10.1038/mp.2011.21

Hill, S.K., Harris, M.S.H., Herbener, E.S., Pavuluri, M., Sweeney, J.A., 2008. Neurocognitive allied phenotypes for schizophrenia and bipolar disorder. Schizophr. Bull. 34, 743–59. https://doi.org/10.1093/schbul/sbn027

Holm, S., 1979. A Simple Sequentially Rejective Multiple Test Procedure. Scand. J. Stat. https://doi.org/10.2307/4615733

Howes, O.D., Kapur, S., 2009. The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway. Schizophr. Bull. 35, 549–562. https://doi.org/10.1093/schbul/sbp006

Jiang, H., Qiao, F., Li, Z., Zhang, Y., Cheng, Y., Xu, X., Yu, L., 2015. Evaluating the association between CACNA1C rs1006737 and schizophrenia risk: A meta-analysis. Asia-Pacific Psychiatry 7, 260–267. https://doi.org/10.1111/appy.12173

Jones, H.J., Stergiakouli, E., Tansey, K.E., Hubbard, L., Heron, J., Cannon, M., Holmans, P., Lewis, G., Linden, D.E.J., Jones, P.B., Davey Smith, G., O’Donovan, M.C., Owen, M.J., Walters, J.T., Zammit, S., 2016. Phenotypic Manifestation of Genetic Risk for Schizophrenia During Adolescence in the General Population. JAMA Psychiatry 73, 221. https://doi.org/10.1001/jamapsychiatry.2015.3058

Kircher, T., Wöhr, M., Nenadic, I., Schwarting, R., Schratt, G., Alferink, J., Culmsee, C., Garn, H., Hahn, T., Müller-Myhsok, B., Dempfle, A., Hahmann, M., Jansen, A., Pfefferle, P., Renz, H., Rietschel, M., Witt, S.H., Nöthen, M., Krug, A., Dannlowski, U., 2018. Neurobiology of the major psychoses: a translational perspective on brain structure and function-the FOR2107 consortium. Eur. Arch. Psychiatry Clin. Neurosci. https://doi.org/10.1007/s00406-018-0943-x

Klein, C., Andresen, B., Jahn, T., 2001. Konstruktvalidierung der deutschsprachigen Adaptation des Schizotypal Personality Questionnaires (SPQ) von Raine (1991), in: Andresen, B., Maß, R. (Eds.), Schizotypie. Psychometrische Entwicklungen Und Biopsychologische Forschungsansätze. Hogrefe, Göttingen, pp. 349–378.

Klein, C., Andresen, B., Jahn, T., 1997. Erfassung der schizotypen Persönlichkeit nach DSM-II-R: Psychometrische Eigenschaften einer autorisierten deutschsprachigen Übersetzung des “Schizotypal Personality Questionnaire” (SPQ) von Raine. Diagnostica 43, 347–369. https://doi.org/10.1037/t10727-000

Kremen, W.., Faraone, S.., Toomey, R., Seidman, L.., Tsuang, M.., 1998. Sex differences in self-reported schizotypal traits in relatives of schizophrenic probands. Schizophr. Res. 34, 27–37. https://doi.org/10.1016/S0920-9964(98)00081-4

Krug, A., Witt, S.H., Backes, H., Dietsche, B., Nieratschker, V., Shah, N.J., Nöthen, M.M., Rietschel, M., Kircher, T., 2014. A genome-wide supported variant in CACNA1C influences hippocampal activation during episodic memory encoding and retrieval. Eur. Arch. Psychiatry Clin. Neurosci. 264, 103–10. https://doi.org/10.1007/s00406-013-0428-x

Kwapil, T.R., Gross, G.M., Silvia, P.J., Barrantes-Vidal, N., 2013. Prediction of psychopathology and functional impairment by positive and negative schizotypy in the Chapmans’ ten-year longitudinal study. J. Abnorm. Psychol. 122, 807–815. https://doi.org/10.1037/a0033759

Lee, P., Lu, W.-S., Liu, C.-H., Lin, H.-Y., Hsieh, C.-L., 2017. Test–Retest Reliability and Minimal Detectable Change of the D2 Test of Attention in Patients with Schizophrenia. Arch. Clin. Neuropsychol. 19. https://doi.org/10.1093/arclin/acx123

Lehrl, S., 1995. Mehrfachwahl-Wortschatz-Intelligenztest MWT-B. Hogrefe, Göttingen.

Lencz, T., Szeszko, P.R., DeRosse, P., Burdick, K.E., Bromet, E.J., Bilder, R.M., Malhotra, A.K., 2010. A Schizophrenia Risk Gene, ZNF804A, Influences Neuroanatomical and Neurocognitive Phenotypes. Neuropsychopharmacology 35, 2284–2291. https://doi.org/10.1038/npp.2010.102

Lufi, D., Segev, S., Blum, A., Rosen, T., Haimov, I., 2015. The Effect of Age on Attention Level. Int. J. Aging Hum. Dev. 81, 176–188. https://doi.org/10.1177/0091415015614953

Machiela, M.J., Chanock, S.J., 2015. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics 31, 3555–7. https://doi.org/10.1093/bioinformatics/btv402

Mohr, C., Claridge, G., 2015. Schizotypy - Do Not Worry, It Is Not All Worrisome. Schizophr. Bull. 41, 436-S443. https://doi.org/10.1093/schbul/sbu185

Mohr, C., Ettinger, U., 2014. An Overview of the Association between Schizotypy and Dopamine. Front. Psychiatry 5, 184. https://doi.org/10.3389/fpsyt.2014.00184

Moon, A.L., Haan, N., Wilkinson, L.S., Thomas, K.L., Hall, J., 2018. CACNA1C: Association With Psychiatric Disorders, Behavior, and Neurogenesis. Schizophr. Bull. 44, 958–965. https://doi.org/10.1093/schbul/sby096

Moreno-Samaniego, L., Gaviria, A.M., Vilella, E., Valero, J., Labad, A., 2017. Schizotypal traits and cognitive performance in siblings of patients with psychosis. Psychiatry Res. 258, 551–556. https://doi.org/10.1016/j.psychres.2017.09.007

Nenadic, I., Maitra, R., Basmanav, F.B., Schultz, C.C., Lorenz, C., Schachtzabel, C., Smesny, S., Nöthen, M.M., Cichon, S., Reichenbach, J.R., Sauer, H., Schlösser, R.G.M.M., Gaser, C., 2015. ZNF804A genetic variation (rs1344706) affects brain grey but not white matter in schizophrenia and healthy subjects. Psychol. Med. 45, 143–152. https://doi.org/10.1017/S0033291714001159

Nettle, D., Clegg, H., 2006. Schizotypy, creativity and mating success in humans. Proc. R. Soc. B Biol. Sci. 273, 611–615. https://doi.org/10.1098/rspb.2005.3349

Nieratschker, V., Brückmann, C., Plewnia, C., 2015. CACNA1C risk variant affects facial emotion recognition in healthy individuals. Sci. Rep. 5, 17349. https://doi.org/10.1038/srep17349

Nuechterlein, K.H., Barch, D.M., Gold, J.M., Goldberg, T.E., Green, M.F., Heaton, R.K., 2004. Identification of separable cognitive factors in schizophrenia. Schizophr. Res. 72, 29–39. https://doi.org/10.1016/j.schres.2004.09.007

O’Donovan, M.C., Craddock, N., Norton, N., Williams, H., Peirce, T., Moskvina, V., Nikolov, I., Hamshere, M., Carroll, L., Georgieva, L., Dwyer, S., Holmans, P., Marchini, J.L., Spencer, C.C.A.A., Howie, B., Leung, H.-T.T., Hartmann, A.M., Möller, H.-J.J., Morris, D.W., Shi, Y.Y., Feng, G.Y., Hoffmann, P., Propping, P., Vasilescu, C., Maier, W., Rietschel, M., Zammit, S., Schumacher, J., Quinn, E.M., Schulze, T.G., Williams, N.M., Giegling, I., Iwata, N., Ikeda, M., Darvasi, A., Shifman, S., He, L., Duan, J., Sanders, A.R., Levinson, D.F., Gejman, P. V., Buccola, N.G., Mowry, B.J., Freedman, R., Amin, F., Black, D.W., Silverman, J.M., Byerley, W.F., Cloninger, C.R., Cichon, S., Nöthen, M.M., Gill, M., Corvin, A., Rujescu, D., Kirov, G., Owen, M.J., Buccola, N.G., Mowry, B.J., Freedman, R., Amin, F., Black, D.W., Silverman, J.M., Byerley, W.F., Cloninger, C.R., Molecular Genetics of Schizophrenia Collaboration, 2008. Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat. Genet. 40, 1053–1055. https://doi.org/10.1038/ng.201

Pardiñas, A.F., Holmans, P., Pocklington, A.J., Escott-Price, V., Ripke, S., Carrera, N., Legge, S.E., Bishop, S., Cameron, D., Hamshere, M.L., Han, J., Hubbard, L., Lynham, A., Mantripragada, K., Rees, E., MacCabe, J.H., McCarroll, S.A., Baune, B.T., Breen, G., Byrne, E.M., Dannlowski, U., Eley, T.C., Hayward, C., Martin, N.G., McIntosh, A.M., Plomin, R., Porteous, D.J., Wray, N.R., Caballero, A., Geschwind, D.H., Huckins, L.M., Ruderfer, D.M., Santiago, E., Sklar, P., Stahl, E.A., Won, H., Agerbo, E., Als, T.D., Andreassen, O.A., Bækvad-Hansen, M., Mortensen, P.B., Pedersen, C.B., Børglum, A.D., Bybjerg-Grauholm, J., Djurovic, S., Durmishi, N., Pedersen, M.G., Golimbet, V., Grove, J., Hougaard, D.M., Mattheisen, M., Molden, E., Mors, O., Nordentoft, M., Pejovic-Milovancevic, M., Sigurdsson, E., Silagadze, T., Hansen, C.S., Stefansson, K., Stefansson, H., Steinberg, S., Tosato, S., Werge, T., GERAD1 Consortium:, D.A., CRESTAR Consortium:, D., Collier, D.A., Rujescu, D., Kirov, G., Owen, M.J., O’Donovan, M.C., Walters, J.T.R., GERAD1 Consortium, CRESTAR Consortium, GERAD1 Consortium, CRESTAR Consortium, 2018. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. Nat. Genet. 50, 381–389. https://doi.org/10.1038/s41588-018-0059-2

Paulus, F.M., Krach, S., Bedenbender, J., Pyka, M., Sommer, J., Krug, A., Knake, S., Nöthen, M.M., Witt, S.H., Rietschel, M., Kircher, T., Jansen, A., 2013. Partial support for ZNF804A genotype-dependent alterations in prefrontal connectivity. Hum. Brain Mapp. 34, 304–313. https://doi.org/10.1002/hbm.21434

Purcell, S., Chang, C., n.d. PLINK v1.9.

R Core Team, 2018. R: A language and environment for statistical computing.

Raine, A., 1992. Sex differences in schizotypal personality in a nonclinical population. J. Abnorm. Psychol. 101, 361–364. https://doi.org/10.1037/0021-843X.101.2.361

Raine, A., 1991. The SPQ: A Scale for the Assessment of Schizotypal Personality Based on DSM-III-R Criteria. Schizophr. Bull. 17, 555–564. https://doi.org/10.1093/schbul/17.4.555

Raine, A., Benishay, D., 1995. The SPQ-B: A Brief Screening Instrument for Schizotypal Personality Disorder. J. Pers. Disord. 9, 346–355. https://doi.org/10.1521/pedi.1995.9.4.346

Riley, B., Thiselton, D., Maher, B.S., Bigdeli, T., Wormley, B., McMichael, G.O., Fanous, A.H., Vladimirov, V., O’Neill, F.A., Walsh, D., Kendler, K.S., 2010. Replication of association between schizophrenia and ZNF804A in the Irish Case-Control Study of Schizophrenia sample. Mol. Psychiatry 15, 29–37. https://doi.org/10.1038/mp.2009.109

Ripke, S., O’Dushlaine, C., Chambert, K., Moran, J.L., Kähler, A.K., Akterin, S., Bergen, S.E., Collins, A.L., Crowley, J.J., Fromer, M., Kim, Y., Lee, S.H., Magnusson, P.K.E., Sanchez, N., Stahl, E.A., Williams, S., Wray, N.R., Xia, K., Bettella, F., Borglum, A.D., Bulik-Sullivan, B.K., Cormican, P., Craddock, N., de Leeuw, C., Durmishi, N., Gill, M., Golimbet, V., Hamshere, M.L., Holmans, P., Hougaard, D.M., Kendler, K.S., Lin, K., Morris, D.W., Mors, O., Mortensen, P.B., Neale, B.M., O’Neill, F.A., Owen, M.J., Milovancevic, M.P., Posthuma, D., Powell, J., Richards, A.L., Riley, B.P., Ruderfer, D., Rujescu, D., Sigurdsson, E., Silagadze, T., Smit, A.B., Stefansson, H., Steinberg, S., Suvisaari, J., Tosato, S., Verhage, M., Walters, J.T., Bramon, E., Corvin, A.P., O’Donovan, M.C., Stefansson, K., Scolnick, E., Purcell, S., McCarroll, S.A., Sklar, P., Hultman, C.M., Sullivan, P.F., Schwab, S.G., Wildenauer, D.B., Dudbridge, F., Holmans, P., Shi, J., Albus, M., Alexander, M., Campion, D., Cohen, D., Dikeos, D., Duan, J., Eichhammer, P., Godard, S., Hansen, M., Lerer, F.B., Liang, K.-Y., Maier, W., Mallet, J., Nertney, D.A., Nestadt, G., Norton, N., O’Neill, F.A., Papadimitriou, G.N., Ribble, R., Sanders, A.R., Silverman, J.M., Walsh, D., Williams, N.M., Wormley, B., Psychosis Endophenotypes International Consortium, Arranz, M.J., Bakker, S., Bender, S., Bramon, E., Collier, D., Crespo-Facorro, B., Hall, J., Iyegbe, C., Jablensky, A., Kahn, R.S., Kalaydjieva, L., Lawrie, S., Lewis, C.M., Lin, K., Linszen, D.H., Mata, I., McIntosh, A., Murray, R.M., Ophoff, R.A., Powell, J., Rujescu, D., Van Os, J., Walshe, M., Weisbrod, M., Wiersma, D., Wellcome Trust Case Control Consortium 2, Donnelly, P., Barroso, I., Blackwell, J.M., Bramon, E., Brown, M.A., Casas, J.P., Corvin, A.P., Deloukas, P., Duncanson, A., Jankowski, J., Markus, H.S., Mathew, C.G., Palmer, C.N.A., Plomin, R., Rautanen, A., Sawcer, S.J., Trembath, R.C., Viswanathan, A.C., Wood, N.W., Spencer, C.C.A., Band, G., Bellenguez, C., Freeman, C., Hellenthal, G., Giannoulatou, E., Pirinen, M., Pearson, R.D., Strange, A., Su, Z., Vukcevic, D., Donnelly, P., Langford, C., Hunt, S.E., Edkins, S., Gwilliam, R., Blackburn, H., Bumpstead, S.J., Dronov, S., Gillman, M., Gray, E., Hammond, N., Jayakumar, A., McCann, O.T., Liddle, J., Potter, S.C., Ravindrarajah, R., Ricketts, M., Tashakkori-Ghanbaria, A., Waller, M.J., Weston, P., Widaa, S., Whittaker, P., Barroso, I., Deloukas, P., Mathew, C.G., Blackwell, J.M., Brown, M.A., Corvin, A.P., McCarthy, M.I., Spencer, C.C.A., Bramon, E., Corvin, A.P., O’Donovan, M.C., Stefansson, K., Scolnick, E., Purcell, S., McCarroll, S.A., Sklar, P., Hultman, C.M., Sullivan, P.F., 2013. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat. Genet. 45, 1150–1159. https://doi.org/10.1038/ng.2742

Roussos, P., Bitsios, P., Giakoumaki, S.G., McClure, M.M., Hazlett, E.A., New, A.S., Siever, L.J., 2013. CACNA1C as a risk factor for schizotypal personality disorder and schizotypy in healthy individuals. Psychiatry Res. 206, 122–123. https://doi.org/10.1016/j.psychres.2012.08.039

Roussos, P., Giakoumaki, S.G., Georgakopoulos, A., Robakis, N.K., Bitsios, P., 2011. The CACNA1C and ANK3 risk alleles impact on affective personality traits and startle reactivity but not on cognition or gating in healthy males. Bipolar Disord. 13, 250–259. https://doi.org/10.1111/j.1399-5618.2011.00924.x

Ruderfer, D.M., Fanous, A.H., Ripke, S., McQuillin, A., Amdur, R.L., Schizophrenia Working Group of the Psychiatric Genomics Consortium, S.W.G. of the P.G., Bipolar Disorder Working Group of the Psychiatric Genomics Consortium, B.D.W.G. of the P.G., Cross-Disorder Working Group of the Psychiatric Genomics Consortium, C.-D.W.G. of the P.G., Gejman, P. V, O’Donovan, M.C., Andreassen, O.A., Djurovic, S., Hultman, C.M., Kelsoe, J.R., Jamain, S., Landén, M., Leboyer, M., Nimgaonkar, V., Nurnberger, J., Smoller, J.W., Craddock, N., Corvin, A., Sullivan, P.F., Holmans, P., Sklar, P., Kendler, K.S., 2014. Polygenic dissection of diagnosis and clinical dimensions of bipolar disorder and schizophrenia. Mol. Psychiatry 19, 1017–1024. https://doi.org/10.1038/mp.2013.138

Schultz, C.C., Nenadic, I., Riley, B., Vladimirov, V.I., Wagner, G., Koch, K., Schachtzabel, C., Mühleisen, T.W., Basmanav, B., Nöthen, M.M., Deufel, T., Kiehntopf, M., Rietschel, M., Reichenbach, J.R., Cichon, S., Schlösser, R.G.M., Sauer, H., 2014. ZNF804A and Cortical Structure in Schizophrenia: In Vivo and Postmortem Studies. Schizophr. Bull. 40, 532–541. https://doi.org/10.1093/schbul/sbt123

Sheldrick, A.J., Krug, A., Markov, V., Leube, D., Michel, T.M., Zerres, K., Eggermann, T., Kircher, T., 2008. Effect of COMT val158met genotype on cognition and personality. Eur. Psychiatry 23, 385–389. https://doi.org/10.1016/j.eurpsy.2008.05.002

Siddi, S., Petretto, D.R., Preti, A., 2017. Neuropsychological correlates of schizotypy: a systematic review and meta-analysis of cross-sectional studies. Cogn. Neuropsychiatry 22, 186–212. https://doi.org/10.1080/13546805.2017.1299702

Smyrnis, N., Avramopoulos, D., Evdokimidis, I., Stefanis, C.N., Tsekou, H., Stefanis, N.C., 2007. Effect of Schizotypy on Cognitive Performance and Its Tuning by COMT val158 Met Genotype Variations in a Large Population of Young Men. Biol. Psychiatry 61, 845–853. https://doi.org/10.1016/j.biopsych.2006.07.019

Snitz, B.E., Macdonald, A.W., Carter, C.S., 2005. Cognitive Deficits in Unaffected First-Degree Relatives of Schizophrenia Patients: A Meta-analytic Review of Putative Endophenotypes. Schizophr. Bull. 32, 179–194. https://doi.org/10.1093/schbul/sbi048

Soeiro-de-Souza, M.G., Otaduy, M.C.G., Dias, C.Z., Bio, D.S., Machado-Vieira, R., Moreno, R.A., 2012. The impact of the CACNA1C risk allele on limbic structures and facial emotions recognition in bipolar disorder subjects and healthy controls. J. Affect. Disord. 141, 94–101. https://doi.org/10.1016/j.jad.2012.03.014

Stefanis, N.C., Hatzimanolis, A., Avramopoulos, D., Smyrnis, N., Evdokimidis, I., Stefanis, C.N., Weinberger, D.R., Straub, R.E., 2013. Variation in psychosis gene ZNF804A is associated with a refined schizotypy phenotype but not neurocognitive performance in a large young male population. Schizophr. Bull. 39, 1252–60. https://doi.org/10.1093/schbul/sbs110

Stotesbury, H., Gaigg, S.B., Kirhan, S., Haenschel, C., 2018. The influence of schizotypal traits on attention under high perceptual load. Schizophr. Res. Cogn. 11, 6–10. https://doi.org/10.1016/j.scog.2017.10.002

Strohmaier, J., Amelang, M., Hothorn, L.A., Witt, S.H., Nieratschker, V., Gerhard, D., Meier, S., Wüst, S., Frank, J., Loerbroks, A., Rietschel, M., Stürmer, T., Schulze, T.G., 2013. The psychiatric vulnerability gene CACNA1C and its sex-specific relationship with personality traits, resilience factors and depressive symptoms in the general population. Mol. Psychiatry 18, 607–613. https://doi.org/10.1038/mp.2012.53

Sun, Y., Hu, D., Liang, J., Bao, Y.-P., Meng, S.-Q., Lu, L., Shi, J., 2015. Association between variants of zinc finger genes and psychiatric disorders: Systematic review and meta-analysis. Schizophr. Res. 162, 124–137. https://doi.org/10.1016/J.SCHRES.2015.01.036

Tesli, M., Skatun, K.C., Ousdal, O.T., Brown, A.A., Thoresen, C., Agartz, I., Melle, I., Djurovic, S., Jensen, J., Andreassen, O.A., 2013. CACNA1C Risk Variant and Amygdala Activity in Bipolar Disorder, Schizophrenia and Healthy Controls. PLoS One 8, e56970. https://doi.org/10.1371/journal.pone.0056970

Thimm, M., Kircher, T., Kellermann, T., Markov, V., Krach, S., Jansen, A., Zerres, K., Eggermann, T., Stöcker, T., Shah, N.J., Nöthen, M.M., Rietschel, M., Witt, S.H., Mathiak, K., Krug, A., 2011. Effects of a CACNA1C genotype on attention networks in healthy individuals. Psychol. Med. 41, 1551–61. https://doi.org/10.1017/S0033291710002217

Toulopoulou, T., Picchioni, M., Rijsdijk, F., Hua-Hall, M., Ettinger, U., Sham, P., Murray, R., 2007. Substantial Genetic Overlap Between Neurocognition and Schizophrenia. Arch. Gen. Psychiatry 64, 1348. https://doi.org/10.1001/archpsyc.64.12.1348

Toulopoulou, T., Van Haren, N., Zhang, X., Sham, P.C., Cherny, S.S., Campbell, D.D., Picchioni, M., Murray, R., Boomsma, D.I., Pol, H.H., Brouwer, R., Schnack, H., Fañanás, L., Sauer, H., Nenadic, I., Weisbrod, M., Cannon, T.D., Kahn, R.S., 2015. Reciprocal causation models of cognitive vs volumetric cerebral intermediate phenotypes for schizophrenia in a pan-European twin cohort. Mol. Psychiatry 20, 1386–1396. https://doi.org/10.1038/mp.2014.152

Toulopoulou, T., Zhang, X., Cherny, S., Dickinson, D., Berman, K.F., Straub, R.E., Sham, P., Weinberger, D.R., 2018. Polygenic risk score increases schizophrenia liability through cognition-relevant pathways. Brain 1–15. https://doi.org/10.1093/brain/awy279

Van Den Bossche, M.J.A., Docx, L., Morrens, M., Cammaerts, S., Strazisar, M., Bervoets, C., Smolders, S., Depreeuw, V., Lenaerts, A.-S., De Rijk, P., Del-Favero, J., Sabbe, B.G.C., 2012. Less cognitive and neurological deficits in schizophrenia patients carrying risk variant in ZNF804A. Neuropsychobiology 66, 158–66. https://doi.org/10.1159/000339731

Voineskos, A.N., Lerch, J.P., Felsky, D., Tiwari, A., Rajji, T.K., Miranda, D., Lobaugh, N.J., Pollock, B.G., Mulsant, B.H., Kennedy, J.L., 2011. The ZNF804A Gene: Characterization of a Novel Neural Risk Mechanism for the Major Psychoses. Neuropsychopharmacology 36, 1871–1878. https://doi.org/10.1038/npp.2011.72

Walters, J.T.R., Corvin, A., Owen, M.J., Williams, H., Dragovic, M., Quinn, E.M., Judge, R., Smith, D.J., Norton, N., Giegling, I., Hartmann, A.M., Möller, H.-J., Muglia, P., Moskvina, V., Dwyer, S., O’Donoghue, T., Morar, B., Cooper, M., Chandler, D., Jablensky, A., Gill, M., Kaladjieva, L., Morris, D.W., O’Donovan, M.C., Rujescu, D., Donohoe, G., 2010. Psychosis Susceptibility Gene ZNF804A and Cognitive Performance in Schizophrenia. Arch. Gen. Psychiatry 67, 692. https://doi.org/10.1001/archgenpsychiatry.2010.81

Williams, H.J., Norton, N., Dwyer, S., Moskvina, V., Nikolov, I., Carroll, L., Georgieva, L., Williams, N.M., Morris, D.W., Quinn, E.M., Giegling, I., Ikeda, M., Wood, J., Lencz, T., Hultman, C., Lichtenstein, P., Thiselton, D., Maher, B.S., Malhotra, A.K., Riley, B., Kendler, K.S., Gill, M., Sullivan, P., Sklar, P., Purcell, S., Nimgaonkar, V.L., Kirov, G., Holmans, P., Corvin, A., Rujescu, D., Craddock, N., Owen, M.J., O’Donovan, M.C., O’Donovan, M.C., 2011. Fine mapping of ZNF804A and genome-wide significant evidence for its involvement in schizophrenia and bipolar disorder. Mol. Psychiatry 16, 429–441. https://doi.org/10.1038/mp.2010.36

Wittchen, H.-U., Wunderlich, U., Gruschwitz, S., Zaudig, M., 1997. SKID-I. Strukturiertes Klinisches Interview für DSM-IV. Hogrefe, Göttingen.

Yasuda, Y., Hashimoto, R., Ohi, K., Fukumoto, M., Umeda-Yano, S., Yamamori, H., Okochi, T., Iwase, M., Kazui, H., Iwata, N., Takeda, M., 2011. Impact on schizotypal personality trait of a genome-wide supported psychosis variant of the ZNF804A gene. Neurosci. Lett. 495, 216–220. https://doi.org/10.1016/j.neulet.2011.03.069

Zhang, F., Chen, Q., Ye, T., Lipska, B.K., Straub, R.E., Vakkalanka, R., Rujescu, D., St. Clair, D., Hyde, T.M., Bigelow, L., Kleinman, J.E., Weinberger, D.R., 2011. Evidence of Sex-Modulated Association of ZNF804A with Schizophrenia. Biol. Psychiatry 69, 914–917. https://doi.org/10.1016/J.BIOPSYCH.2011.01.003

Zhang, Q., Shen, Q., Xu, Z., Chen, M., Cheng, L., Zhai, J., Gu, H., Bao, X., Chen, X., Wang, K., Deng, X., Ji, F., Liu, C., Li, J., Dong, Q., Chen, C., 2012. The Effects of CACNA1C Gene Polymorphism on Spatial Working Memory in Both Healthy Controls and Patients with Schizophrenia or Bipolar Disorder. Neuropsychopharmacology 37, 677–684. https://doi.org/10.1038/npp.2011.242

**Figure legends**

**Figure1.** Sex-moderated *models 1a* and *1b* of the effect of *ZNF804A* rs1344706-C and *CACNA1C* rs1006737-A on differential schizotypy dimensions. *b1-3* indicate unstandardised regression coefficients for each path; statistically significant paths are shown in bold.

**Figure2.** Sex-moderated mediation *model 3a* of the effect of *ZNF804A* rs1344706-C on d2 performance, mediated by *Cognitive-Perceptual* schizotypy. Conceptual (A) and statistical (B) diagram. *a1-d2* indicate unstandardised regression coefficients for each path; statistically significant paths are shown in bold.

**Figure3.** Sex-moderated mediation *model 3b* of the effect of *ZNF804A* rs1344706-C on *Cognitive-Perceptual* schizotypy, mediated by d2 performance. Conceptual (A) and statistical (B) diagram. *a1-d2* indicate unstandardised regression coefficients for each path; statistically significant paths are shown in bold.

**Table 1.** Distribution of schizotypy and allele frequencies for both sexes.

|  |  |  |  |
| --- | --- | --- | --- |
|  | **total**mean (SDa) | **male**mean (SDa) | **female**mean (SDa) |
| **SPQ-B** |  |  |  |
| Sum | 3.42 (2.99) | 3.78 (3.07) | 3.20 (2.93) |
| *Cognitive Perceptual* | 0.90 (1.15) | 0.81 (1.03) | 0.95 (1.21) |
| *Interpersonal* | 1.72 (1.72) | 1.92 (1.76) | 1.60 (1.68) |
| *Disorganized* | 0.80 (1.27) | 1.04 (1.43) | 0.65 (1.15) |
|  | **total**no. (%) | **male**no. (%) | **female**no. (%) |
| ***ZNF804A* rs1344706** |  |  |  |
| AA | 217 (35.3) | 85 (36.6) | 132 (34.5) |
| AC | 295 (48.9) | 106 (45.7) | 189 (49.3) |
| CC | 103 (16.7) | 41 (17.7) | 62 (16.2) |
| ***CACNA1C* rs1006737** |  |  |  |
| GG | 292 (47.5) | 118 (50.9) | 174 (45.4) |
| AG | 267 (43.4) | 99 (42.7) | 168 (43.9) |
| AA | 56 (9.1) | 15 (6.5) | 41 (10.7) |

a*SD = standard deviation.*

|  |  |
| --- | --- |
| ***model 1a*** | **(*F*(2,614) = 16.00, *p* = 1.7×10-7, *R²* = 0.050)** |
| *prediction of* Cognitive-Perceptual *schizotypy* | √mPRESSb = 1.12 |
|  | coefficient (sea) | *t* | *p* | *padj* |
| age | 0.018 (0.004) | 4.34 | 5.05×10-7 | **2.53×10-6** |
| rs1344706 × sex | 0.283 (0.124) | 2.28 | 0.015 | **0.033** |
|  rs1344706 (sex=m) | -0.073 (0.094) | -0.74 | 0.458 |  |
|  rs1344706 (sex=f) | 0.212 (0.079) | 2.79 | 0.007 |  |
|  |  |
| ***model 1b*** | **(*F*(2,614) = 16.58, *p* = 0.003, *R²* = 0.015)** |
| *prediction of* Interpersonal *schizotypy* | √mPRESSb = 1.71 |
|  | coefficient (sea) | *t* | *p* | *padj* |
| age | 0.011 (0.006) | 2.02 | 0.044 | **0.044** |
| rs1006737 × sex | 0.283 (0.124) | -2.57 | 0.011 | **0.033** |
|  rs1006737 (sex=m) | -0.399 (0.188) | -2.13 | 0.035 |  |
|  rs1006737 (sex=f) | -0.162 (0.129) | -1.26 | 0.209 |  |
|  |  |
| ***model 2*** | **(*F*(4,610) = 38.89, *p* =**  **5.13×10-29, *R²* = 0.203)** |
| *prediction of d2 performance* | √mPRESSb = 37.99 |
|  | coefficient (sea) | *t* | *p* | *padj* |
| age | -1.342 (0.125) | -10.76 | 7.85×10-25 | **3.14×10-24** |
| rs1344706 | -15.551 (5.208) | -2.99 | 0.003 | **0.006** |
| rs1344706 × sex | 6.553 (2.944) | 2.23 | 0.026 | **0.026** |
|  rs1344706 (sex=m) | -8.145 (3.399) | -2.40 | 0.017 |  |
|  rs1344706 (sex=f) | -3.041 (2.881) | -1.06 | 0.292 |  |
| *Cognitive-Perceptual* schizotypy | -4.509 (1.367) | -3.30 | 0.001 | **0.003** |

**Table 2.** Summary of model specifications for *models 1a, 1b and 2.* Full documentation in suppl. Tables S1-S2.

*In bold Bonferroni-Holm-adjusted p-values after correction;* a*SE = standard error;* b*√mPRESS = root mean predicted residual sum of squares.*